<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445484</url>
  </required_header>
  <id_info>
    <org_study_id>J06102 CDR0000532944</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J06102</secondary_id>
    <secondary_id>JHOC-NA_00006008</secondary_id>
    <secondary_id>CELGENE-CC-5013</secondary_id>
    <nct_id>NCT00445484</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in
      different ways and stop cancer cells from growing. Vaccines may help the body build an
      effective immune response to kill cancer cells. Giving lenalidomide together with vaccine
      therapy may make a stronger immune response and kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine
      therapy works in treating patients with relapsed or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether lenalidomide can augment the efficacy of pneumococcal polyvalent
           vaccine as it correlates with lenalidomide-induced antitumor efficacy in patients with
           relapsed or refractory multiple myeloma.

      Secondary

        -  Determine the antibody responses to pneumococcal serotypes in patients treated with this
           regimen.

        -  Determine T-cell responses to the carrier protein CRM 197 in patients treated with this
           regimen.

        -  Determine the ability of lenalidomide to augment in vivo immune responsiveness as
           measured by cutaneous delayed-type hypersensitivity (DTH) reactions to Candida and
           tetanus in these patients.

        -  Determine the ability of lenalidomide to prime and/or boost systemic vaccine responses
           in both peripheral blood lymphocytes and marrow lymphocytes in these patients.

      OUTLINE: Patients are assigned to 1 of 2 treatment groups.

        -  Group 1: Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28
           days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
           Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to
           beginning lenalidomide and again in approximately 2 months (after the first dose of the
           vaccine).

        -  Group 2: Patients receive lenalidomide as in group 1. Patients receive pneumococcal
           polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in
           approximately 2 months (after the first dose of the vaccine).

      After completion of study treatment, patients are followed at 30 days.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6B Antibody Response to Prevnar Vaccine in Peripheral Blood</measure>
    <time_frame>basline and 8 weeks after second vaccination</time_frame>
    <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>14F Antibody Response to Prevnar Vaccine in Peripheral Blood</measure>
    <time_frame>basline and 8 weeks after second vaccination</time_frame>
    <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>19F Antibody Response to Prevnar Vaccine in Peripheral Blood</measure>
    <time_frame>basline and 8 weeks after second vaccination</time_frame>
    <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>23F Antibody Response to Prevnar Vaccine in Peripheral Blood</measure>
    <time_frame>basline and 8 weeks after second vaccination</time_frame>
    <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcal polyvalent vaccine</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma (MM) meeting all of the following criteria:

               -  Relapsed or refractory disease

               -  Previously received ≥ 2 courses of antimyeloma treatment

          -  Measurable levels of myeloma paraprotein in serum (&gt; 0.5 g/dL) or urine (&gt; 0.2
             g/24-hour urine collection) OR serum-free light-chain disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 75,000/mm^3

          -  Creatinine ≤ 2.5 mg/dL

          -  Bilirubin ≤ 2.0 mg/dL

          -  AST and ALT ≤ 3 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of highly effective contraception ≥ 4 weeks
             before, during, and for 4 weeks after completion of study therapy

          -  No other malignancy within the past 5 years except treated basal cell or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix or breast

          -  No serious medical condition, laboratory abnormality, or psychiatric illness that
             would preclude study treatment or put patient at unacceptable risk

          -  No known hypersensitivity to thalidomide or lenalidomide

               -  No development of erythema nodosum in the presence of a reaction characterized by
                  a desquamating rash while taking thalidomide or similar drugs

          -  No known hypersensitivity to any component of the pneumococcal polyvalent vaccine,
             including diphtheria toxin or CRM 197

          -  No known HIV positivity

          -  No infectious hepatitis type A, B, or C

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than 3 prior treatment regimens for MM

          -  More than 6 months since prior lenalidomide

          -  More than 28 days since prior experimental drug or therapy

          -  More than 1 month since prior systemic antimyeloma therapy

          -  More than 1 month since prior and no concurrent systemic corticosteroids

          -  No other concurrent anticancer agents or treatments or investigational agents

          -  No concurrent thalidomide

          -  No concurrent radiotherapy

          -  No other concurrent immune therapy or immunomodulatory agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Borrello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012 Mar 1;18(5):1426-34. doi: 10.1158/1078-0432.CCR-11-1221. Epub 2012 Jan 12.</citation>
    <PMID>22241792</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 24, 2015</results_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 2</title>
          <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Group 1</title>
          <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 22 patients were enrolled, 11 in each cohort. Patients who showed evidence of disease progression while on study were not included in subsequent analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="9.0"/>
                    <measurement group_id="B2" value="65.8" spread="10.3"/>
                    <measurement group_id="B3" value="66.0" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6B Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
        <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
        <time_frame>basline and 8 weeks after second vaccination</time_frame>
        <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Started 14 Days Prior to Lenalidomide</title>
            <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Vaccine Started 45 Days After Lenalidomide</title>
            <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>6B Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
          <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
          <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="1.1"/>
                    <measurement group_id="O2" value="7.58" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>14F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
        <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
        <time_frame>basline and 8 weeks after second vaccination</time_frame>
        <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Started 14 Days Prior to Lenalidomide</title>
            <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Vaccine Started 45 Days After Lenalidomide</title>
            <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>14F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
          <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
          <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="5.0"/>
                    <measurement group_id="O2" value="11.95" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>19F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
        <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
        <time_frame>basline and 8 weeks after second vaccination</time_frame>
        <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Started 14 Days Prior to Lenalidomide</title>
            <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Vaccine Started 45 Days After Lenalidomide</title>
            <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>19F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
          <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
          <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.025" spread="0.64"/>
                    <measurement group_id="O2" value="2.12" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>23F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
        <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
        <time_frame>basline and 8 weeks after second vaccination</time_frame>
        <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Started 14 Days Prior to Lenalidomide</title>
            <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Vaccine Started 45 Days After Lenalidomide</title>
            <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>23F Antibody Response to Prevnar Vaccine in Peripheral Blood</title>
          <description>Serum IgG levels against the PVC serotype were measured by ELISA</description>
          <population>Patients who showed evidence of disease progression while on study were not included in the analysis.</population>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.8"/>
                    <measurement group_id="O2" value="2.42" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
pneumococcal polyvalent vaccine: Given intramuscularly
lenalidomide: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath on exertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ivan Borrello</name_or_title>
      <organization>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>(410) 955-4967</phone>
      <email>iborrell@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

